FDA approves pimicotinib for symptomatic tenosynovial giant cell tumor
The agency cleared the kinase inhibitor, sold as Pimjetmi, for adults whose TGCT surgery could cause worse function or severe morbidity.
FDA
8 stories
The agency cleared the kinase inhibitor, sold as Pimjetmi, for adults whose TGCT surgery could cause worse function or severe morbidity.
FDA
The agency approved the EMD Serono drug, marketed as Tepmetko, on February 15, 2024 for adults with metastatic non-small cell lung cancer carrying MET exon 14 skipping alterations.
Drugs@FDA, FDA (2)
Bio-Techne's board approved an $0.08 per share payout that will only go forward if the company's pending acquisition by Merck KGaA has not closed by the record date.
SEC filing
Pfizer lifted full-year revenue and EPS guidance on third-quarter results and detailed regulatory approvals for Talzenna, Tukysa and a positive Elrexfio Phase 3 readout.
SEC filing (9)
The agreements provide free cetuximab supply for a Phase I trial combining Adlai Nortye's investigational ADC AN4035 with the EGFR antibody in RAS-addicted solid tumors.
SEC filing